ThromboGenics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, ThromboGenics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

ThromboGenics: 12 sponsored US clinical trials, none currently recruiting.

ThromboGenics sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetic Macular Edema, with 2 trials.

Top-decile sponsor footprint

ThromboGenics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

11 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 1

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

NCT03666923
COMPLETED Phase 1

A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)

NCT03511898
TERMINATED Phase 2

A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR

NCT02681809
COMPLETED

A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA

NCT02193945
COMPLETED

Ocriplasmin Research to Better Inform Treatment (ORBIT)

NCT02079883
COMPLETED Phase 3

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

NCT01429441
COMPLETED

Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies

NCT01287988
COMPLETED Phase 2

Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy

NCT00986362
COMPLETED Phase 2

Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion

NCT00913744
COMPLETED Phase 3

Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.

NCT00798317
COMPLETED Phase 3

Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.

NCT00781859
COMPLETED Phase 2

A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)

NCT00412958

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 3

Therapeutic Areas

Diabetic Macular Edema 2
Diabetic Retinopathy 2
Diabetes Mellitus 2
Vitrectomy 1

How the ThromboGenics early-phase archive is shaped

12 indexed studies, none listed as recruiting (0% open); 11 completed (92%).

Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Diabetic Macular Edema (2 trials), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

ThromboGenics: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

ThromboGenics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share ThromboGenicsAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
ThromboGenics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

ThromboGenics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this ThromboGenics page

12 registered trials is a research-attention snapshot, not an endorsement of ThromboGenics or any single study.

  • None of ThromboGenics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Diabetic Macular Edema is the condition ThromboGenics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Macular Edema trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

ThromboGenics pipeline card: 12 registered trials from official public datasets.Report a data error.